| |
Age (years)
|
Sex
|
Primary
|
T category
|
Node positive
|
Tumor size (mm)
|
Tumor number
|
Regimen
|
No. of lines
|
No. of cycles
|
Clinical response
|
Resection
|
|---|
|
1
|
65
|
M
|
Colon
|
3
|
+
|
80
|
≥5
|
Cmab + FOLFIRI
|
1
|
3
|
PR
|
1
|
|
2
|
57
|
M
|
Rectum
|
3
|
+
|
50
|
≥5
|
Bmab + FOLFOX6
|
1
|
17
|
PR
|
0
|
|
3
|
52
|
F
|
Colon
|
4
|
+
|
30
|
≥5
|
Cmab + FOLFIRI
|
1
|
3
|
PR
|
1
|
|
4
|
51
|
M
|
Colon
|
3
|
−
|
20
|
2–4
|
Bmab + FOLFOX6
|
1
|
18
|
PR
|
0
|
|
5
|
60
|
M
|
Rectum
|
4
|
+
|
50
|
≥5
|
Cmab + FOLFOX6
|
1
|
7
|
PR
|
1
|
|
6
|
67
|
M
|
Colon
|
4
|
−
|
30
|
≥5
|
Cmab + FOLFOX6
|
1
|
8
|
PR
|
1
|
|
7
|
78
|
M
|
Colon
|
3
|
−
|
20
|
≥5
|
Cmab + FOLFOX6
|
1
|
15
|
PR
|
1
|
|
8
|
32
|
F
|
Colon
|
3
|
+
|
100
|
≥5
|
Bmab + FOLFOX6
|
1
|
8
|
SD
|
1
|
|
9
|
80
|
F
|
Colon
|
3
|
−
|
32
|
≥5
|
Bmab + FOLFOX6
|
1
|
4
|
PR
|
0
|
|
10
|
44
|
F
|
Colon
|
3
|
+
|
100
|
≥5
|
Cmab + FOLFOX6
|
1
|
3
|
SD
|
0
|
|
11
|
33
|
F
|
Colon
|
3
|
+
|
24
|
≥5
|
Bmab + FOLFOX6
|
1
|
2
|
PR
|
0
|
|
12
|
56
|
F
|
Colon
|
3
|
−
|
80
|
2–4
|
Cmab + FOLFOX6
|
1
|
3
|
PR
|
0
|
|
13
|
58
|
M
|
Colon
|
3
|
+
|
40
|
≥5
|
Cmab + FOLFIRI/Bmab + Xelox
|
2
|
18
|
PR
|
1
|
|
14
|
55
|
F
|
Colon
|
4
|
−
|
55
|
≥5
|
Cmab + FOLFOX6
|
1
|
3
|
PR
|
0
|
|
15
|
58
|
F
|
Rectum
|
3
|
+
|
40
|
1
|
Cmab + FOLFOX6
|
1
|
3
|
SD
|
0
|
|
16
|
65
|
M
|
Rectum
|
3
|
−
|
23
|
≥5
|
Pmab + FOLFOX6
|
1
|
3
|
PR
|
0
|
-
M male, F female, Cmab cetuximab, Bmab bevacizumab, PR partial response, SD stable disease
